Abstract:Mucosal immunity is the main defense line against respiratory disease pathogens. Newcastle disease and avian infectious bronchitis are common respiratory diseases in poultry. However, the mucosal immune response is not sufficiently activated and thus fails to achieve the ideal immune protection. Therefore, it is important to develop a suitable mucosal immune adjuvant to enhance the immune response of live vaccines. Here, the bursal-derived peptide BP7, β-glucan, and hyaluronic acid were selected as the adjuvant to be assembled into the composite nanopolypeptide adjuvant (CNPB7) with ultrasonic dispersion technology. The results showed that after optimizing assembly conditions, the optimal average particle size of nanoparticle CNPB7 was 514.9 nm and PDI was 0.298. To evaluate the non-specific immune responses of nanoparticle CNPB7, the chickens were immunized only with nanoparticle CNPB7. It was confirmed that nanoparticle CNPB7 enhanced the expression of CD3, CD4, CD80, and CD86 factors in the spleen lymphocyte from the chicken immunized with nanoparticle CNPB7. To investigate the mucosal immune response of nanoparticle CNPB7, the chickens were orally immunized with Newcastle disease virus (NDV)–infectious bronchitis virus (IBV) dual vaccines and CNPB7. The results proved that the levels of immunoglobulin SIgA, IL-4, IFN-γ, and IL-13 in the mucus samples from the respiratory and digestive tract in chicken immunized with nanoparticle CNPB7 and vaccines were significantly increased, compared to that of vaccine control. Finally, it was observed that nanoparticle CNPB7 promoted specific increased antibody productions against NDV and IBV in the immunized chicken. These results proved that the assembled nanoparticle CNPB7 could enhance the vaccination efficacy in chicken, which provided the experimental basis for the development of new adjuvants, and offered technical support for preventing virus transmission of avian diseases.

A new recombinant hybrid polypeptide and its immunologic adjuvant activity for inactivated infectious bursal disease vaccine

Plasmid DNA encoding antigens of infectious bursal disease viruses induce protective immune responses in chickens: factors influencing efficacy.

[Enhanced Immunogenicity of Plasmid Encoding Polyprotein Gene of Infectious Bursal Disease Virus by Co-Administration of Chicken Interleukin 2 (IL-2)].

Enhancement of the Immunogenicity of DNA Vaccine Against Infectious Bursal Disease Virus by Co-Delivery with Plasmid Encoding Chicken Interleukin 2.

Immunoenhancement on DNA Vaccine of Polyprotein Gene in Infectious Bursal Disease Virus by Co-Delivery with Plasmid Encoding Chicken Interleukin-18.

Induction of Protective Immune Response in Chickens Immunized with Plasmid DNA Encoding Antigens of Infectious Bursal Disease Virus

Lactococcus Lactisanchoring Avian Infectious Bronchitis Virus Multi-Epitope Peptide EpiC Induced Specific Immune Responses in Chickens

The Immunogenicity of CO-expressing Plasmid and Fusion Genes Plasmid Containing IBDV VP2/4/3 and ChIL-18 Genes

Fused IgY Fc and Polysaccharide Adjuvant Enhanced the Immune Effect of the Recombinant VP2 and VP5 Subunits—A Prospect for Improvement of Infectious Bursal Disease Virus Subunit Vaccine

Synthesis of Reassortant Infectious Bursal Disease Virus in Chickens Injected Directly with Infectious Clones from Different Virus Strains

Study on the Immunogenicity of Infectious Bursal Disease Virus VP2 Proteins Expressed in Silkworm

Gene cloning, expression and immune adjuvant properties of the recombinant fusion peptide Tα1-BLP on avian influenza inactivate virus vaccine

Bursal peptide BP-IV as a novel immunoadjuvant enhances the protective efficacy of an epitope peptide vaccine containing T and B cell epitopes of the H9N2 avian influenza virus

Eimeria tenella: ginsenosides-enhanced immune response to the immunization with recombinant 5401 antigen in chickens.

Recombinant chicken interleukin-7 as a potent adjuvant increases the immunogenicity and protection of inactivated infectious bursal disease vaccine

Evaluation of the immune responses of biological adjuvant bivalent vaccine with three different insertion modes for ND and IBD

Preparation of ChIL-2 and IBDV VP2 Fusion Protein by Baculovirus Expression System

Construction and Evaluation of the Immunogenicity and Protective Efficacy of Recombinant Replication-Deficient Human Adenovirus-5 Expressing Genotype VII Newcastle Disease Virus F Protein and Infectious Bursal Disease Virus VP2 Protein

The Immunomodulatory Function of Assembled Composite Nanopolypeptide Containing Bursal-Derived BP7 (CNPB7) in Promoting the Mucosal Immune Response within Poultry Immunization

Oral DNA vaccination with the polyprotein gene of infectious bursal disease virus (IBDV) delivered by attenuated Salmonella elicits protective immune responses in chickens

Administration of Infectious Bursal Disease Vaccine in Houhai Acupoint Promotes Robust Immune Responses in Chickens.